

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1774763/publications.pdf>

Version: 2024-02-01

327
papers

7,457
citations

61857

43
h-index

106150

65
g-index

332
all docs

332
docs citations

332
times ranked

9111
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric study. <i>Comprehensive Psychiatry</i> , 2008, 49, 218-223.	1.5	344
2	Decreased plasma antioxidants in patients with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 344-348.	1.3	253
3	Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise. <i>Current Neuropharmacology</i> , 2009, 7, 331-336.	1.4	174
4	Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 46, 224-235.	2.5	124
5	Why Systematic Review rather than Narrative Review?. <i>Psychiatry Investigation</i> , 2015, 12, 417.	0.7	123
6	Possible association between ??G308A tumour necrosis factor-?? gene polymorphism and major depressive disorder in the Korean population. <i>Psychiatric Genetics</i> , 2003, 13, 179-181.	0.6	107
7	A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 653-656.	0.7	106
8	Does minocycline have antidepressant effect?. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 308-311.	2.5	98
9	The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. <i>International Clinical Psychopharmacology</i> , 2008, 23, 1-8.	0.9	95
10	Psychometric Properties of the Patient Health Questionnaire-15 (PHQ-15) for Measuring the Somatic Symptoms of Psychiatric Outpatients. <i>Psychosomatics</i> , 2009, 50, 580-585.	2.5	88
11	Effects of Olanzapine on Prolactin Levels of Female Patients With Schizophrenia Treated With Risperidone. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 408-413.	1.1	88
12	Omega-3 Polyunsaturated Fatty Acids in Prevention of Mood and Anxiety Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 129-137.	0.9	85
13	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 851-870.	1.4	83
14	A review of current evidence for acetyl-L-carnitine in the treatment of depression. <i>Journal of Psychiatric Research</i> , 2014, 53, 30-37.	1.5	80
15	Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder. <i>CNS Drugs</i> , 2011, 25, 109-127.	2.7	79
16	Pain and Depression: A Neurobiological Perspective of Their Relationship. <i>Psychiatry Investigation</i> , 2015, 12, 1.	0.7	77
17	Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. <i>International Clinical Psychopharmacology</i> , 2005, 20, 311-314.	0.9	72
18	An open pilot trial of olanzapine for delirium in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2001, 55, 515-519.	1.0	71

#	ARTICLE	IF	CITATIONS
19	Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. <i>Psychopharmacology</i> , 2009, 206, 479-489.	1.5	70
20	Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: A pilot study on differential effects of sex hormones on antidepressant effects. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 228-235.	2.5	67
21	Aripiprazole in the Treatment of Depressive and Anxiety Disorders. <i>CNS Drugs</i> , 2008, 22, 367-388.	2.7	66
22	A pilot trial of quetiapine for the treatment of patients with delirium. <i>Human Psychopharmacology</i> , 2004, 19, 125-127.	0.7	64
23	Transdermal Selegiline: <i>The New Generation of Monoamine Oxidase Inhibitors</i>. <i>CNS Spectrums</i> , 2006, 11, 363-375.	0.7	64
24	A Double-Blind, Randomized, Placebo-Controlled Trial of Paroxetine Controlled-Release in Irritable Bowel Syndrome. <i>Psychosomatics</i> , 2009, 50, 78-86.	2.5	64
25	Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. <i>International Immunopharmacology</i> , 2006, 6, 666-671.	1.7	60
26	Multimodal Cognitive Enhancement Therapy for Patients with Mild Cognitive Impairment and Mild Dementia: A Multi-Center, Randomized, Controlled, Double-Blind, Crossover Trial. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 787-796.	1.2	59
27	The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. <i>Contemporary Clinical Trials</i> , 2009, 30, 116-122.	0.8	58
28	Altered Verbal Working Memory Process in Patients with Alzheimer's Disease. <i>Neuropsychobiology</i> , 2008, 57, 181-187.	0.9	57
29	Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1561-1570.	0.9	57
30	A 6 Week Randomized Double-Blind Placebo-Controlled Trial of Ziprasidone for the Acute Depressive Mixed State. <i>PLoS ONE</i> , 2012, 7, e34757.	1.1	56
31	Atypical Depression. <i>CNS Drugs</i> , 2009, 23, 1023-1037.	2.7	55
32	Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. <i>Neuroscience Letters</i> , 2005, 383, 22-27.	1.0	53
33	Safety and Tolerability of Lamotrigine. <i>Clinical Neuropharmacology</i> , 2011, 34, 39-47.	0.2	53
34	Influence of <i>BDNF</i> Variants on Diagnosis and Response to Treatment in Patients with Major Depression, Bipolar Disorder and Schizophrenia. <i>Neuropsychobiology</i> , 2012, 65, 1-11.	0.9	53
35	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 174-186.	1.4	53
36	The relationship between fibromyalgia and major depressive disorder: a comprehensive review. <i>Current Medical Research and Opinion</i> , 2008, 24, 2359-2371.	0.9	52

#	ARTICLE	IF	CITATIONS
37	Paroxetine: safety and tolerability issues. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 783-794.	1.0	51
38	Triple Reuptake Inhibitors: The Next Generation of Antidepressants. <i>Current Neuropharmacology</i> , 2008, 6, 338-343.	1.4	49
39	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. <i>European Neuropsychopharmacology</i> , 2009, 19, 562-570.	0.3	49
40	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2015, 64, 88-98.	1.5	47
41	Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 495-500.	1.0	45
42	Quetiapine XR: Current status for the treatment of major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1165-1173.	2.5	44
43	Atypical Antipsychotic Augmentation Strategies in the Context of Guideline-based Care for the Treatment of Major Depressive Disorder. <i>CNS Drugs</i> , 2013, 27, 29-37.	2.7	44
44	Mirtazapine may have the propensity for developing a restless legs syndrome? A case report. <i>Psychiatry and Clinical Neurosciences</i> , 2002, 56, 209-210.	1.0	43
45	Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. <i>Neuroscience Research</i> , 2005, 52, 211-219.	1.0	43
46	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. <i>Psychiatry Research</i> , 2011, 189, 26-32.	1.7	42
47	Omega-3 polyunsaturated fatty acids for major depressive disorder. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1519-1534.	1.9	41
48	Fine mapping of a schizophrenia susceptibility locus at chromosome 6q23: increased evidence for linkage and reduced linkage interval. <i>European Journal of Human Genetics</i> , 2005, 13, 763-771.	1.4	40
49	Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. <i>Journal of Psychiatric Research</i> , 2008, 42, 35-40.	1.5	39
50	A review of the safety and tolerability of aripiprazole. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 373-386.	1.0	39
51	Milnacipran. <i>Clinical Neuropharmacology</i> , 2009, 32, 355-363.	0.2	39
52	Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1196-1201.	2.5	38
53	Polymorphism of the Cytosolic Phospholipase A ₂ Gene and Mood Disorders in the Korean Population. <i>Neuropsychobiology</i> , 2004, 49, 185-188.	0.9	37
54	Heat-shock protein-70 genes and response to antidepressants in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1006-1011.	2.5	37

#	ARTICLE	IF	CITATIONS
55	Low-frequency, Repetitive Transcranial Magnetic Stimulation for the Treatment of Patients with Posttraumatic Stress Disorder: a Double-blind, Sham-controlled Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2013, 11, 96-102.	0.9	37
56	Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. <i>Journal of Psychiatric Research</i> , 2017, 84, 292-300.	1.5	37
57	Curcumin as a putative antidepressant. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 269-280.	1.4	36
58	Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1413-1418.	2.5	35
59	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 469-480.	0.9	35
60	Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. <i>Neuroscience Research</i> , 2005, 53, 8-13.	1.0	34
61	BanI polymorphism of the cytosolic phospholipase A2 gene may confer susceptibility to the development of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 739-741.	2.5	33
62	Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. <i>Psychiatry Research</i> , 2004, 127, 279-281.	1.7	33
63	Manganese superoxide dismutase (MnSOD: Ala→Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. <i>Psychiatry Research</i> , 2007, 153, 77-81.	1.7	33
64	Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1143-1145.	2.5	32
65	A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 490-496.	2.5	32
66	A case of brief psychosis associated with an arachnoid cyst. <i>Psychiatry and Clinical Neurosciences</i> , 2002, 56, 203-205.	1.0	31
67	Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , 2004, 14, 147-150.	0.6	31
68	Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 199-205.	1.8	31
69	A review of current evidence for vilazodone in major depressive disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 160-169.	1.2	31
70	Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. <i>Human Psychopharmacology</i> , 2002, 17, 341-344.	0.7	30
71	Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. <i>Depression and Anxiety</i> , 2007, 24, 522-526.	2.0	30
72	Birth order and sibling sex ratio in homosexual transsexual South Korean men: Effects of the male-preference stopping rule. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 529-533.	1.0	30

#	ARTICLE	IF	CITATIONS
73	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 305-311.	1.8	30
74	Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study. <i>Journal of Psychiatric Research</i> , 2015, 66-67, 84-94.	1.5	30
75	Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. <i>International Clinical Psychopharmacology</i> , 2005, 20, 173-176.	0.9	29
76	Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 347-351.	1.0	29
77	Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 701-703.	1.1	29
78	Does Neurotrophin-3 Have a Therapeutic Implication in Major Depression?. <i>International Journal of Neuroscience</i> , 2008, 118, 1515-1522.	0.8	28
79	The association of personality trait on treatment outcomes in patients with chronic prostatitis/chronic pelvic pain syndrome: An exploratory study. <i>Journal of Psychosomatic Research</i> , 2014, 76, 127-133.	1.2	28
80	Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students. <i>Academic Psychiatry</i> , 2014, 38, 661-667.	0.4	28
81	Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 399-403.	1.0	27
82	Head motion analysis during cognitive fMRI examination: Application in patients with schizophrenia. <i>Neuroscience Research</i> , 2005, 53, 84-90.	1.0	27
83	Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 69-75.	0.7	27
84	Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1219-1223.	2.5	27
85	Tardive dystonic symptoms associated with aripiprazole treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 589-590.	2.5	27
86	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. <i>Journal of Psychiatric Research</i> , 2014, 56, 72-81.	1.5	27
87	Therapeutic implication of cocaine- and amphetamine-regulated transcript (CART) in the treatment of depression. <i>Medical Hypotheses</i> , 2007, 69, 132-135.	0.8	26
88	The Impact of Heat Shock Protein 70 Gene Variations on Clinical Presentation and Outcome in Schizophrenic Inpatients. <i>Neuropsychobiology</i> , 2009, 59, 135-141.	0.9	26
89	Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. <i>Psychiatry Investigation</i> , 2015, 12, 155.	0.7	26
90	Selegiline transdermal system: Current awareness and promise. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1153-1163.	2.5	25

#	ARTICLE	IF	CITATIONS
91	Mixed depression: A study of its phenomenology and relation to treatment response. <i>Journal of Affective Disorders</i> , 2012, 136, 1059-1061.	2.0	24
92	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. <i>BMC Psychiatry</i> , 2016, 16, 106.	1.1	24
93	Safety of Selegiline Transdermal System in Clinical Practice. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 661-668.	1.1	24
94	Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 115-121.	2.5	23
95	Temperament and character dimensions in patients with atopic dermatitis. <i>Journal of Dermatology</i> , 2006, 33, 10-15.	0.6	23
96	Dysbindin gene (DTNBP1) and schizophrenia in Korean population. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 137-142.	1.8	23
97	Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 215-223.	0.9	23
98	Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. <i>Psychiatry Research</i> , 2012, 198, 39-46.	1.7	23
99	Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole. <i>Clinical Neuropharmacology</i> , 2013, 36, 223-238.	0.2	23
100	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. <i>Neuropsychobiology</i> , 2016, 74, 159-168.	0.9	23
101	The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 217.	0.7	23
102	Interleukin-17 and Interleukin-22 Induced Proinflammatory Cytokine Production in Keratinocytes via Inhibitor of Nuclear Factor κ B Kinase Expression. <i>Annals of Dermatology</i> , 2012, 24, 398.	0.3	23
103	Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 519-523.	2.5	22
104	Association study of catechol-O-methyltransferase gene polymorphism in Korean male alcoholics. <i>Psychiatric Genetics</i> , 2005, 15, 151-154.	0.6	22
105	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. <i>Psychiatry Research</i> , 2013, 209, 121-123.	1.7	22
106	Venlafaxine versus Mirtazapine in the Treatment of Undifferentiated Somatoform Disorder. <i>Clinical Drug Investigation</i> , 2008, 28, 251-261.	1.1	21
107	Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. <i>International Clinical Psychopharmacology</i> , 2009, 24, 29-33.	0.9	21
108	Influence of the number and severity of somatic symptoms on the severity of depression and suicidality in community-dwelling elders. <i>Asia-Pacific Psychiatry</i> , 2014, 6, 274-283.	1.2	21

#	ARTICLE	IF	CITATIONS
109	CACNA1C gene and schizophrenia. <i>Psychiatric Genetics</i> , 2015, 25, 163-167.	0.6	21
110	Triple Reuptake Inhibitors: A Premise and Promise. <i>Psychiatry Investigation</i> , 2008, 5, 142.	0.7	21
111	The Relationship between Depression, Anxiety, Somatization, Personality and Symptoms of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. <i>Psychiatry Investigation</i> , 2015, 12, 268.	0.7	21
112	Neuronal Dysfunction of the Frontal Lobe in Schizophrenia. <i>Neuropsychobiology</i> , 2004, 50, 211-215.	0.9	20
113	The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: A 24-week continuation therapy. <i>Psychiatry and Clinical Neurosciences</i> , 2005, 59, 743-747.	1.0	20
114	Experiences and barriers to implementation of clinical practice guideline for depression in Korea. <i>BMC Psychiatry</i> , 2013, 13, 150.	1.1	20
115	The Influence of Depression, Anxiety and Somatization on the Clinical Symptoms and Treatment Response in Patients with Symptoms of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. <i>Journal of Korean Medical Science</i> , 2014, 29, 1145.	1.1	20
116	Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study. <i>Journal of Psychiatric Research</i> , 2014, 49, 75-82.	1.5	20
117	Perspectives on the Happiness of Community-Dwelling Elderly in Korea. <i>Psychiatry Investigation</i> , 2016, 13, 50.	0.7	20
118	Beyond serotonin: newer antidepressants in the future. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 777-790.	1.4	20
119	Trends in Scientific Literature on Atypical Antipsychotics in South Korea: A Bibliometric Study. <i>Psychiatry Investigation</i> , 2013, 10, 8.	0.7	20
120	No Effect of Serotonergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. <i>Psychiatry Investigation</i> , 2013, 10, 180.	0.7	20
121	Report on IL-10 gene polymorphism at position -819 for major depression and schizophrenia in Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2002, 56, 177-180.	1.0	19
122	Manganese superoxide dismutase (MnSOD: Ala→9Val) gene polymorphism and mood disorders: A preliminary study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1326-1329.	2.5	19
123	Thyroid hormones affect recovery from depression during antidepressant treatment. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 305-313.	1.0	19
124	TAAR6 variations possibly associated with antidepressant response and suicidal behavior. <i>Psychiatry Research</i> , 2010, 180, 20-24.	1.7	19
125	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014, 18, 97-102.	1.2	19
126	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 235-248.	0.9	19

#	ARTICLE	IF	CITATIONS
127	Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 46-53.	0.7	19
128	Polymorphism of CTLA-4 gene at position 49 of exon 1 may be associated with schizophrenia in the Korean population. <i>Psychiatry Research</i> , 2002, 110, 19-25.	1.7	18
129	fMRI investigation on cue-induced smoking craving. <i>Journal of Psychiatric Research</i> , 2005, 39, 333-335.	1.5	18
130	Ghrelin precursor gene polymorphism and methamphetamine dependence in the Korean population. <i>Neuroscience Research</i> , 2005, 53, 391-395.	1.0	18
131	Interrelationships among Pain, Disability, and Psychological Factors in Young Korean Conscripts with Lumbar Disc Herniation. <i>Military Medicine</i> , 2006, 171, 1113-1116.	0.4	18
132	Pregabalin augmentation to antidepressants in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 577-578.	2.5	18
133	Clinical Issues in Use of Atypical Antipsychotics for Depressed Patients. <i>CNS Drugs</i> , 2013, 27, 39-45.	2.7	18
134	The association between the severity of poststroke depression and clinical outcomes after first-onset stroke in Korean patients. <i>General Hospital Psychiatry</i> , 2015, 37, 245-250.	1.2	18
135	Fibromyalgia diagnosis: a review of the past, present and future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 667-679.	1.4	18
136	Investigational dopamine antagonists for the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 687-698.	1.9	18
137	Rapid Versus Conventional Initiation of Quetiapine in the Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 399-405.	1.1	18
138	Treatment of Chronic Fatigue Syndrome: Findings, Principles and Strategies. <i>Psychiatry Investigation</i> , 2008, 5, 209.	0.7	18
139	Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 153-159.	1.0	17
140	TNFB polymorphism may be associated with schizophrenia in the Korean population. <i>Schizophrenia Research</i> , 2003, 61, 39-45.	1.1	17
141	Polymorphism of the Serotonin Transporter Gene and Symptomatic Dimensions of Schizophrenia in the Korean Population. <i>Neuropsychobiology</i> , 2003, 47, 182-186.	0.9	17
142	Open label study of the effect of amantadine on weight gain induced by olanzapine. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 163-167.	1.0	17
143	Depression and Somatic Symptoms May Influence on Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Preliminary Study. <i>Psychiatry Investigation</i> , 2014, 11, 495.	0.7	17
144	The Association between Post-Stroke Depression and the Activities of Daily Living/Gait Balance in Patients with First-Onset Stroke Patients. <i>Psychiatry Investigation</i> , 2016, 13, 659.	0.7	17

#	ARTICLE	IF	CITATIONS
145	Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 375-379.	2.5	16
146	Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 565-572.	1.9	16
147	Do We Need to Consider Ethno-cultural Variation in the Use of Atypical Antipsychotics for Asian Patients with Major Depressive Disorder?. <i>CNS Drugs</i> , 2013, 27, 47-51.	2.7	16
148	Tianeptine combination for partial or non-response to selective serotonin reuptake inhibitor monotherapy. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 219-227.	1.0	16
149	Augmentation of Aripiprazole for Depressed Patients With an Inadequate Response to Antidepressant Treatment. <i>Clinical Neuropharmacology</i> , 2013, 36, 157-161.	0.2	16
150	Efficacy of antidepressants: bias in randomized clinical trials and related issues. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 15-25.	1.3	16
151	Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. <i>Human Psychopharmacology</i> , 2003, 18, 453-456.	0.7	15
152	Monocyte Chemoattractant Protein-1 Promoter -2518 Polymorphism May Have an Influence on Clinical Heterogeneity of Bipolar I Disorder in the Korean Population. <i>Neuropsychobiology</i> , 2004, 49, 111-114.	0.9	15
153	Psychological burdens are associated with young male transsexuals in Korea. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 417-421.	1.0	15
154	DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. <i>Neuroscience Letters</i> , 2008, 440, 150-154.	1.0	15
155	TAAR 6 and HSP-70 variations associated with bipolar disorder. <i>Neuroscience Letters</i> , 2009, 465, 257-261.	1.0	15
156	Investigation of an epistatic effect between a set of TAAR6 and HSP70 genes variations and major mood disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 680-683.	1.1	15
157	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. <i>Neuroscience Letters</i> , 2012, 506, 170-174.	1.0	15
158	Precision medicine for psychopharmacology: a general introduction. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 831-839.	1.4	15
159	Characteristics of neurocognitive functions in mild cognitive impairment with depression. <i>International Psychogeriatrics</i> , 2016, 28, 1181-1190.	0.6	15
160	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. <i>Advances in Therapy</i> , 2017, 34, 713-724.	1.3	15
161	Measurement-based Treatment of Residual Symptoms Using Clinically Useful Depression Outcome Scale: Korean Validation Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 28-34.	0.9	15
162	Increased plasma complement factor H is associated with geriatric depression. <i>International Psychogeriatrics</i> , 2019, 31, 101-108.	0.6	15

#	ARTICLE	IF	CITATIONS
163	Polymorphism of CTLA-4 gene for major depression in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2001, 55, 533-537.	1.0	14
164	Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , 2004, 14, 65-67.	0.6	14
165	No evidence for interaction between 5-HT _{2A} receptor and serotonin transporter genes in schizophrenia. <i>Neuroscience Research</i> , 2005, 52, 195-199.	1.0	14
166	Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 437-444.	2.5	14
167	TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study. <i>European Psychiatry</i> , 2008, 23, 390-395.	0.1	14
168	Desvenlafaxine in the treatment of major depressive disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2923-2928.	0.9	14
169	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. <i>Advances in Therapy</i> , 2018, 35, 1656-1670.	1.3	14
170	Tumor necrosis factor-beta gene polymorphism may not be associated with major depressive disorder in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 31-35.	1.0	13
171	Aberration of cholesterol level in first-onset bipolar I patients. <i>Journal of Affective Disorders</i> , 2004, 83, 79-82.	2.0	13
172	Paroxetine-associated spontaneous sexual stimulation. <i>International Clinical Psychopharmacology</i> , 2005, 20, 339-341.	0.9	13
173	Predictors of Early Worsening after Switch to Aripiprazole. <i>Clinical Drug Investigation</i> , 2010, 30, 187-193.	1.1	13
174	Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 481.	0.7	13
175	Polymorphisms of interleukin-4 promoter and receptor gene for schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 283-288.	1.0	12
176	Amisulpride versus Risperidone Treatment for Behavioral and Psychological Symptoms in Patients with Dementia of the Alzheimer Type: A Randomized, Open, Prospective Study. <i>Neuropsychobiology</i> , 2006, 54, 247-251.	0.9	12
177	Desvenlafaxine: a new antidepressant or just another one?. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 875-887.	0.9	12
178	Methylphenidate Extended Release (OROS MPH) for the Treatment of Antidepressant-Related Sexual Dysfunction in Patients With Treatment-Resistant Depression. <i>Clinical Neuropharmacology</i> , 2009, 32, 85-88.	0.2	12
179	Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1541-1552.	1.4	12
180	Paliperidone-associated atypical neuroleptic malignant syndrome: A case report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 650-651.	2.5	12

#	ARTICLE	IF	CITATIONS
181	Association of estrogen receptor genes and schizophrenia: A preliminary study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 1-4.	2.5	12
182	Management of Chronic Depressive Patients with Residual Symptoms. <i>CNS Drugs</i> , 2013, 27, 53-57.	2.7	12
183	Role of the cholinesterase inhibitors in the treatment of schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 293-298.	1.9	12
184	Criticisms of drugs in early development for the treatment of depression: what can be improved?. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 445-453.	1.9	12
185	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. <i>Journal of Affective Disorders</i> , 2019, 249, 410-417.	2.0	12
186	Innovations in Clinical Research Design and Conduct in Psychiatry: Shifting to Pragmatic Approaches. <i>Psychiatry Investigation</i> , 2009, 6, 1.	0.7	12
187	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for <i>CACNA1C</i> , <i>CHRNA7</i> and <i>MAPK1</i> . <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 364-368.	0.9	12
188	The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 495-502.	0.9	12
189	Human leukocyte antigen alleles in patients with bipolar disorder in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , 2002, 56, 453-457.	1.0	11
190	History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 435-441.	1.3	11
191	Epistasis between a set of variations located in the <i>TAAR6</i> and <i>HSP-70</i> genes toward schizophrenia and response to antipsychotic treatment. <i>European Neuropsychopharmacology</i> , 2009, 19, 806-811.	0.3	11
192	Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2013, 28, 322-329.	0.9	11
193	Agomelatine: a new option for treatment of depression?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 443-447.	0.9	11
194	Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. <i>CNS Spectrums</i> , 2014, 19, 324-329.	0.7	11
195	A 13-Week, Randomized Double-Blind, Placebo-Controlled, Cross-Over Trial of Ziprasidone in Bipolar Spectrum Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 319-323.	0.7	11
196	The Influence of <i>AHI1</i> Variants on the Diagnosis and Treatment Outcome in Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2015, 16, 2517-2529.	1.8	11
197	<i>PDE7B</i> , <i>NMBR</i> and <i>EPM2A</i> Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. <i>Neuropsychobiology</i> , 2016, 73, 160-168.	0.9	11
198	Relationship between Depression and Laryngopharyngeal Reflux. <i>Psychiatry Investigation</i> , 2017, 14, 226.	0.7	11

#	ARTICLE	IF	CITATIONS
199	Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective. <i>Psychiatry Investigation</i> , 2009, 6, 55.	0.7	11
200	Injured temporomandibular joint associated with fluoxetine-monotherapy-induced repeated yawning. <i>General Hospital Psychiatry</i> , 2003, 25, 217-218.	1.2	10
201	Association of low dose trazodone treatment with aggravated angle-closure glaucoma. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 127-128.	1.0	10
202	Additive effect between quinine oxidoreductase gene (NQO1: Pro187Ser) and manganese superoxide dismutase gene (MnSOD: Ala-9Val) polymorphisms on tardive dyskinesia in patients with schizophrenia. <i>Psychiatry Research</i> , 2008, 161, 336-338.	1.7	10
203	Verbal Working Memory Dysfunction in Schizophrenia: An fMRI Investigation. <i>International Journal of Neuroscience</i> , 2008, 118, 1467-1487.	0.8	10
204	Desvenlafaxine Succinate: A Newer Antidepressant for the Treatment of Depression and Somatic Symptoms. <i>Postgraduate Medicine</i> , 2010, 122, 125-138.	0.9	10
205	Can botulinum toxin improve mood in depressed patients?. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1049-1051.	1.4	10
206	Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 197-205.	1.0	10
207	A Korean validation study of the Clinically Useful Anxiety Outcome Scale: Comorbidity and differentiation of anxiety and depressive disorders. <i>PLoS ONE</i> , 2017, 12, e0179247.	1.1	10
208	Very low dose quetiapine-induced galactorrhea in combination with venlafaxine. <i>Human Psychopharmacology</i> , 2004, 19, 433-434.	0.7	9
209	Risperidone in combination with mood stabilizers for acute mania: a multicentre, open study. <i>International Clinical Psychopharmacology</i> , 2004, 19, 299-303.	0.9	9
210	Long-term treatment of adjunctive quetiapine for bipolar mania. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 763-766.	2.5	9
211	Influence of TAAR6 polymorphisms on response to aripiprazole. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 822-826.	2.5	9
212	History of depressive and/or anxiety disorders as a predictor of treatment response: A post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 996-1002.	2.5	9
213	Paroxetine mesylate: comparable to paroxetine hydrochloride?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 185-193.	0.9	9
214	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. <i>Psychiatry Research</i> , 2010, 178, 430-432.	1.7	9
215	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. <i>Neuroscience Letters</i> , 2012, 508, 37-41.	1.0	9
216	Sertindole: dilemmas for its use in clinical practice. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 321-326.	1.0	9

#	ARTICLE	IF	CITATIONS
217	Olanzapine-Induced Diabetic Ketoacidosis and Neuroleptic Malignant Syndrome with Rhabdomyolysis: A Case Report. <i>Endocrinology and Metabolism</i> , 2013, 28, 70.	1.3	9
218	A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises. <i>Psychiatry Investigation</i> , 2014, 11, 371.	0.7	9
219	Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 371-377.	0.9	9
220	Posttraumatic Embitterment Disorder in Patients with Chronic Kidney Disease. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 183-188.	0.9	9
221	Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 153-158.	0.9	9
222	Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. <i>Human Psychopharmacology</i> , 2004, 19, 25-29.	0.7	8
223	Switching to quetiapine in patients with acute mania who were intolerant to risperidone. <i>Human Psychopharmacology</i> , 2004, 19, 47-51.	0.7	8
224	Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial. <i>International Clinical Psychopharmacology</i> , 2005, 20, 327-330.	0.9	8
225	DRD2/ANKK1 TaqI A polymorphism affects corticostriatal activity in response to negative affective facial stimuli. <i>Behavioural Brain Research</i> , 2011, 223, 36-41.	1.2	8
226	Do we need more than one antidepressant for patients with major depressive disorder?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1561-1564.	1.4	8
227	Early switch strategy in patients with major depressive disorder. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1185-1188.	1.4	8
228	Caseâ€“control association study of GRIA1, GRIA2 and GRIA4 polymorphisms in bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 18-26.	1.2	8
229	Investigation of Epistasis Between <i>DAOA</i> and <i>5HTR1A</i> Variants on Clinical Outcomes in Patients with Schizophrenia. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 504-507.	0.3	8
230	Aripiprazole augmentation for major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 116-119.	0.9	8
231	Five potential therapeutic agents as antidepressants: a brief review and future directions. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1015-1029.	1.4	8
232	Formula for predicting OSA and the Apneaâ€“Hypopnea Index in Koreans with suspected OSA using clinical, anthropometric, and cephalometric variables. <i>Sleep and Breathing</i> , 2017, 21, 885-892.	0.9	8
233	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 901-910.	1.8	8
234	VNTR Polymorphism of Tyrosine Hydroxylase Gene and Schizophrenia in the Korean Population. <i>Neuropsychobiology</i> , 2003, 47, 131-136.	0.9	7

#	ARTICLE	IF	CITATIONS
235	Potential role of lymphotoxin-alpha (tumor necrosis factor-beta) in the development of schizophrenia. <i>Medical Hypotheses</i> , 2007, 68, 1359-1362.	0.8	7
236	Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 593-593.	1.0	7
237	Risperidone in the treatment of mixed state bipolar patients: Results from a 24-week, multicenter, open-label study in Korea. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 28-37.	1.0	7
238	No association between genetic markers in BDNF gene and lithium prophylaxis in a Greek sample. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 154-157.	1.2	7
239	Association of sedative-hypnotic medications with suicidality. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 345-349.	1.4	7
240	Investigation of possible epistatic interactions between <i>GRIA2</i> and <i>GRIA4</i> variants on clinical outcomes in patients with major depressive disorder. <i>Journal of International Medical Research</i> , 2013, 41, 809-815.	0.4	7
241	Comments on "Low plasma BDNF is associated with suicidal behavior in major depression" by Y.K. Kim et al. <i>Progress in Neuropsychopharmacology and Biological Psychiatry</i> 2006 Aug 9; [Epub ahead of print]. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 578-579.	2.5	6
242	Monocyte chemoattractant protein-1 (MCP1) may play a role in depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 313-314.	2.5	6
243	A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression: Is there differential effect of ropinirole dose on developing psychotic symptom?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1087-1088.	2.5	6
244	No influence of FAT polymorphisms in response to aripiprazole. <i>Journal of Human Genetics</i> , 2010, 55, 32-36.	1.1	6
245	Relationship between the course of depression symptoms and the left ventricular mass index and left ventricular filling pressure in chronic haemodialysis patients. <i>Nephrology</i> , 2011, 16, 180-186.	0.7	6
246	How much to worry about the FDA warning in the use of citalopram?. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 883-886.	1.4	6
247	Pramipexole augmentation in treatment-resistant major depressive disorder. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 5-8.	1.4	6
248	Cognitive Dysfunction in Psychiatric Illness: A Neglected Domain. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e375-e377.	1.1	6
249	Duloxetine: An emerging evidence for fibromyalgia. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 69-71.	2.5	5
250	Reduced Cannabis Use After Low-Dose Naltrexone Addition to Opioid Detoxification. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 476-478.	0.7	5
251	No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. <i>Neuropsychobiology</i> , 2010, 62, 245-249.	0.9	5
252	Achieving and Sustaining Remission in Bipolar I Disorder with Ziprasidone. <i>Clinical Drug Investigation</i> , 2012, 32, 747-754.	1.1	5

#	ARTICLE	IF	CITATIONS
253	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 273-286.	1.1	5
254	Provoked bradycardia after paroxetine administration. <i>General Hospital Psychiatry</i> , 2003, 25, 142-144.	1.2	4
255	Quantification analysis of 123I-IPT single photon emission computed tomography uptake in the striatum of parkinsonism with the standard magnetic resonance template. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 18-28.	1.0	4
256	Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. <i>Human Psychopharmacology</i> , 2006, 21, 367-375.	0.7	4
257	Quinone oxidoreductase (NQO1) gene polymorphism may not confer a susceptibility to mood disorders. <i>Psychiatry Research</i> , 2007, 153, 83-86.	1.7	4
258	Therapeutic possibilities of cysteamine in the treatment of schizophrenia. <i>Medical Hypotheses</i> , 2007, 69, 199-202.	0.8	4
259	Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea. <i>Human Psychopharmacology</i> , 2007, 22, 351-359.	0.7	4
260	Psychometric properties of the Korean version of the Short Post-Traumatic Stress Disorder Rating Interview (K-SPRINT). <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 34-39.	1.0	4
261	Potential role of pregabalin in the treatment of lithium-induced tremor: a case report. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 879-81.	1.0	4
262	Pregabalin for Treating Bipolar Mania. <i>Clinical Neuropharmacology</i> , 2009, 32, 364.	0.2	4
263	DAOA variants and schizophrenia: Influence on diagnosis and treatment outcomes. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 303-310.	1.2	4
264	Use of antidepressants for depression in patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 255-257.	0.9	4
265	Scopolamine as an Antidepressant. <i>Clinical Neuropharmacology</i> , 2013, 36, 102.	0.2	4
266	Low-dose escitalopram-associated hyponatremia. <i>Asia-Pacific Psychiatry</i> , 2013, 5, E90.	1.2	4
267	Oral scopolamine augmentation for major depression. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 19-21.	1.4	4
268	Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting. <i>Asia-Pacific Psychiatry</i> , 2014, 6, 334-341.	1.2	4
269	The association between personality traits and treatment outcomes in Korean patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a preliminary study. <i>General Hospital Psychiatry</i> , 2014, 36, 545-548.	1.2	4
270	Evidence-Based Treatment for Depressive Disorder. <i>Psychiatry Investigation</i> , 2015, 12, 278.	0.7	4

#	ARTICLE	IF	CITATIONS
271	An open-label, single-arm pilot study to evaluate the efficacy of daily low dose tadalafil on depression in patients with erectile dysfunction. <i>Translational Andrology and Urology</i> , 2019, 8, 501-506.	0.6	4
272	Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder. <i>Psychiatry Investigation</i> , 2008, 5, 102.	0.7	4
273	Development of a Diverse Learning Experience for Diverse Psychiatry Resident Needs: A Four-Year Biological Psychiatry Curriculum Incorporating Principles of Neurobiology, Psychopharmacology, and Evidence-Based Practice. <i>Psychiatry Investigation</i> , 2017, 14, 289.	0.7	4
274	Comments on "Short-Term Testosterone Augmentation in Male Schizophrenics: A Randomized, Double-Blind, Placebo-Controlled Trial" by Dr Ko and Colleagues. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 194-195.	0.7	3
275	Comments on "Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials". <i>General Hospital Psychiatry</i> , 2010, 32, 448.	1.2	3
276	Selegiline transdermal system in major depressive disorder. <i>Neuropsychiatry</i> , 2012, 2, 125-134.	0.4	3
277	Dilemma for enhancing psychiatrists' adherence to guideline (evidence)-based practice. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 751-754.	1.4	3
278	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. <i>Advances in Therapy</i> , 2017, 34, 1482-1497.	1.3	3
279	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. <i>Journal of Molecular Neuroscience</i> , 2018, 64, 62-74.	1.1	3
280	Even Low-Dose Treatment of Venlafaxine May Provoke Recurrence of Hypertension in An Asian Patient?. <i>General Hospital Psychiatry</i> , 2001, 23, 232-234.	1.2	2
281	Comments on "Association between Ala9Val polymorphism of MnSOD gene and schizophrenia" by O. Akyol et al. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> 29, 2005, 123-131. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 762-763.	2.5	2
282	Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: A retrospective study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1322-1325.	2.5	2
283	Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: A case report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 386-387.	2.5	2
284	Supersensitivity psychosis and aripiprazole tapering. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 748-749.	2.5	2
285	A Severe Case of Bupropion Hydrochloride Extended-Release Monotherapy-Associated Visual Hallucinations and Delirium in a Female Patient with Major Depressive Disorder. <i>CNS Spectrums</i> , 2010, 15, 601-602.	0.7	2
286	No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 228-232.	1.2	2
287	Quetiapine augmentation for depression. <i>International Clinical Psychopharmacology</i> , 2015, 30, 54-58.	0.9	2
288	Sickness absence indicating depressive symptoms of working population in South Korea. <i>Journal of Affective Disorders</i> , 2018, 227, 443-449.	2.0	2

#	ARTICLE	IF	CITATIONS
289	Availability of brain serotonin transporters (5HTT) is associated with low positive mood in healthy elderly subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 533-539.	0.3	2
290	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. <i>Psychiatry Investigation</i> , 2014, 11, 200.	0.7	2
291	A naturalistic study of risperidone treatment in seven affiliated university hospitals in Korea. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 83-89.	1.0	1
292	No evidence for an association of the CTLA4 gene with bipolar I disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 21-24.	1.0	1
293	Fluoxetine-induced mania in an Asian patient. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 448-449.	1.0	1
294	No association of TAP2 polymorphisms in Korean patients with schizophrenia. <i>Psychiatric Genetics</i> , 2004, 14, 173-176.	0.6	1
295	Comments on MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2006, 141B, 193-194.	1.1	1
296	Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1149-1150.	2.5	1
297	Therapeutic Possibility of <i>Seamax</i> for Depression. <i>CNS Spectrums</i> , 2008, 13, 20-21.	0.7	1
298	Milnacipran for Chronic Pain in the Orofacial Region. <i>Clinical Neuropharmacology</i> , 2010, 33, 270.	0.2	1
299	Rash and lamotrigine in bipolar patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 256-257.	2.5	1
300	Accelerating response to antidepressant treatment in depression: A possible role for atypical antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 434.	2.5	1
301	Early versus conventional switching of antidepressant: a post-hoc analysis of clinical trial data for major depressive disorder with moderate to severe pain symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2711-2715.	0.9	1
302	Association between antidepressants and breast/ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 441-444.	0.9	1
303	Attitudes on clinical research participation of community living elders in Korea. <i>Asia-Pacific Psychiatry</i> , 2012, 4, 168-173.	1.2	1
304	Comment on: The relationship between statins and depression: a review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2449-2451.	0.9	1
305	Comments on "What is a rational antidepressant treatment for major depression in patients with Parkinson's disease?". <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 65-66.	1.0	1
306	Curcumin as an Add-on to Antidepressive Treatment. <i>Clinical Neuropharmacology</i> , 2013, 36, 242-243.	0.2	1

#	ARTICLE	IF	CITATIONS
307	Patient Preference and Satisfaction in Decision-Making Process. Journal of Korean Medical Science, 2014, 29, 1030.	1.1	1
308	The Potential Role of Scopolamine as Antidepressant for Mood Disorder. Clinical Neuropharmacology, 2014, 37, 67-68.	0.2	1
309	Filicide: Needing Psychiatrists' Attention. Psychiatry Investigation, 2014, 11, 214.	0.7	1
310	Serotonin Receptor 2C -759C/T Polymorphism and Weight Change or Treatment Response to Mirtazapine in Korean Depressive Patients. Psychiatry Investigation, 2014, 11, 342.	0.7	1
311	Strategies to Find Candidate Genes for Bipolar Disorder. Psychiatry Investigation, 2009, 6, 316.	0.7	1
312	Critics on "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study". Psychiatry Investigation, 2013, 10, 98.	0.7	1
313	Clinical variables associated with early administration of antipsychotics in bipolar mania. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 151-154.	2.5	0
314	Effectiveness of carbamazepine for benzodiazepine-resistant impulsive aggression in a patient with frontal infarctions. Psychiatry and Clinical Neurosciences, 2008, 62, 483-483.	1.0	0
315	Comments on "Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder". Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 597-598.	2.5	0
316	Comments on "Addition of lamotrigine to valproic acid: A successful outcome in a case of rapid-cycling bipolar affective disorder". Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 595-596.	2.5	0
317	Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study. Current Therapeutic Research, 2008, 69, 221-231.	0.5	0
318	Reply to Dr Ng's Comments on "A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation With An Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression". Journal of Clinical Psychopharmacology, 2008, 28, 117-118.	0.7	0
319	Corrigendum to: "TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study" [Eur Psychiatr 2008;23:390-5]. European Psychiatry, 2009, 24, 64-64.	0.1	0
320	Follow-up study of suicide attempters who were given crisis intervention during hospital stay: Pilot study. Psychiatry and Clinical Neurosciences, 2010, 64, 107-107.	1.0	0
321	Effect of quetiapine-XR on irritable bowel syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1162-1163.	2.5	0
322	Antipsychotics and Abnormal Liver Function Tests. Clinical Neuropharmacology, 2012, 35, 297-298.	0.2	0
323	Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease. Expert Review of Neurotherapeutics, 2012, 12, 155-158.	1.4	0
324	Comment and reply on: Antidepressant for depressed patients with pain. Expert Opinion on Investigational Drugs, 2013, 22, 167-168.	1.9	0

#	ARTICLE	IF	CITATIONS
325	Influence of Media on Suicide: Proper Coverage of Media on Suicide Report. Journal of Korean Medical Science, 2014, 29, 1583.	1.1	0
326	Will the Proteus sensor enhance adherence to aripiprazole or other antipsychotics?. Expert Review of Neurotherapeutics, 2017, 17, 319-321.	1.4	0
327	Augmentation of Dopaminergic Agents for Major Depressive Disorder. Journal of Clinical Psychiatry, 2009, 70, 432-433.	1.1	0